Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis

Arthritis and Rheumatism

Volumn 65, Issue 1, 2013, Pages 236-246

  Fuschiotti, Patrizia ^a   Larregina, Adriana T ^a   Ho, Johnan ^a   Feghali Bostwick, Carol ^a   Medsger, Thomas A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; INTERLEUKIN 13; RECEPTOR; SCLEROPROTEIN; SKIN HOMING RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SKIN FIBROBLAST; SKIN FIBROSIS; SUPERNATANT; SYSTEMIC SCLEROSIS; WESTERN BLOTTING;

EID: 84871768637     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37706     Document Type: Article

References (49)

1. Gabrielli A, Avvedimento EV, Krieg T,. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
2. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
3. Jinnin M,. Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol 2010; 37: 11-25.
4. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP,. Lymphocytes in the skin of patients with progressive systemic sclerosis: quantification, subtyping, and clinical correlations. Arthritis Rheum 1984; 27: 645-53.
5. Fleischmajer R, Perlish JS, Reeves JR,. Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977; 20: 975-84.
6. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P,. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992; 166: 255-63.
7. Kahaleh MB,. Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 2004; 16: 718-22.
8. Scharffetter K, Lankat-Buttgereit B, Krieg T,. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988; 18: 9-17.
9. Kraling BM, Maul GG, Jimenez SA,. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995; 63: 48-56.
10. Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L,. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005; 64: 1233-5.
11. Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD,. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002; 168: 3649-59.
12. Chizzolini C,. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol 2008; 20: 707-12.
13. Fuschiotti P, Medsger TA Jr, Morel PA,. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum 2009; 60: 1119-28.
14. Medsger TA Jr, Ivanco DE, Kardava L, Morel PA, Lucas MR, Fuschiotti P,. GATA-3 up-regulation in CD8+ T cells is a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. Arthritis Rheum 2011; 63: 1738-47.
15. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K,. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997; 24: 328-32.
16. Aliprantis AO, Wang J, Fathman JW, Lemaire R, Dorfman DM, Lafyatis R, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A 2007; 104: 2827-30.
17. Greenblatt MB, Sargent JL, Farina G, Tsang K, Lafyatis R, Glimcher LH, et al. Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol 2012; 180: 1080-94.
18. H2 paradigm. Nat Rev Immunol 2004; 4: 583-94.
19. Johnson RW, Tew MB, Arnett FC,. The genetics of systemic sclerosis. Curr Rheumatol Rep 2002; 4: 99-107.
20. Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, Henry P, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999; 42: 1168-78.
21. Parel Y, Aurrand-Lions M, Scheja A, Dayer JM, Roosnek E, Chizzolini C,. Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum 2007; 56: 3459-67.
22. + T cells in systemic sclerosis. Immunol Res 2011; 50: 188-94.
23. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
24. LeRoy EC, Medsger TA Jr,. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
25. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
26. Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, Steen VD, et al. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 2007; 56: 2740-6.
27. Medsger TA Jr,. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003; 29: 255-73, vi.
28. Chizzolini C, Parel Y, de Luca C, Tyndall A, Akesson A, Scheja A, et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor α. Arthritis Rheum 2003; 48: 2593-604.
29. Jinnin M, Ihn H, Yamane K, Tamaki K,. Interleukin-13 stimulates the transcription of the human α2(I) collagen gene in human dermal fibroblasts. J Biol Chem 2004; 279: 41783-91.
30. Aoudjehane L, Pissaia A Jr, Scatton O, Podevin P, Massault PP, Chouzenoux S, et al. Interleukin-4 induces the activation and collagen production of cultured human intrahepatic fibroblasts via the STAT-6 pathway. Lab Invest 2008; 88: 973-85.
31. Lonsdorf AS, Hwang ST, Enk AH,. Chemokine receptors in T-cell-mediated diseases of the skin. J Invest Dermatol 2009; 129: 2552-66.
32. Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002; 8: 157-65.
33. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS,. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997; 389: 978-81.
34. + skin homing T cells. J Immunol 2002; 169: 1189-96.
35. Katsumoto TR, Whitfield ML, Connolly MK,. The pathogenesis of systemic sclerosis. Annu Rev Pathol 2011; 6: 509-37.
36. Gupta RA, Fiorentino D,. Localized scleroderma and systemic sclerosis: is there a connection? Best Pract Res Clin Rheumatol 2007; 21: 1025-36.
37. Makris D, Lazarou S, Alexandrakis M, Kourelis TV, Tzanakis N, Kyriakou D, et al. Tc2 response at the onset of COPD exacerbations. Chest 2008; 134: 483-8.
38. Betts RJ, Kemeny DM,. CD8+ T cells in asthma: friend or foe? Pharmacol Ther 2009; 121: 123-31.
39. + T cells mediate inflammation and airway hyper-responsiveness. Nat Med 2004; 10: 865-9.
40. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC,. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001; 194: 1541-7.
41. Hayakawa I, Hasegawa M, Matsushita T, Yanaba K, Kodera M, Komura K, et al. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis. Rheumatology (Oxford) 2005; 44: 873-8.
42. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A,. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999; 190: 815-26.
43. Kahaleh MB, Fan PS,. Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 1997; 83: 32-40.
44. Vukmanovic-Stejic M, Vyas B, Gorak-Stolinska P, Noble A, Kemeny DM,. Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes. Blood 2000; 95: 231-40.
45. Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Canonica GW, Jasmin C, Azzarone B,. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts: implication in asthma. J Clin Invest 1998; 101: 2129-39.
46. Andrews AL, Holloway JW, Puddicombe SM, Holgate ST, Davies DE,. Kinetic analysis of the interleukin-13 receptor complex. J Biol Chem 2002; 277: 46073-8.
47. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD,. Interleukin-4 and interleukin-13 signaling connections maps. Science 2003; 300: 1527-8.
48. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A,. IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis. Nat Med 2006; 12: 99-106.
49. Granel B, Allanore Y, Chevillard C, Arnaud V, Marquet S, Weiller PJ, et al. IL13RA2 gene polymorphisms are associated with systemic sclerosis. J Rheumatol 2009; 33: 2015-9.